Sun Pharma Advanced Research Company · NSE: SPARC · BSE: 532872
Q2 FY20 results · Jul–Sep 2019
Sun Pharma Advanced Research Company reported revenue from operations of ₹17.19 crore (down 72.0% from Q2 FY19) and net loss of ₹63.16 crore for Q2 FY20 (Jul–Sep 2019), on a standalone basis.
| Item | Q2 FY20 | Q2 FY19 | YoY | Q1 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 17.19 | 61.35 | −72.0% | 17.32 | −0.8% |
| Other income | 2.26 | 4.57 | −50.5% | 3.67 | −38.4% |
| Total income | 19.45 | 65.92 | −70.5% | 20.99 | −7.3% |
| Profit before tax | (63.16) | (2.58) | Loss widened | (94.19) | Loss narrowed |
| Net profit for the period | (63.16) | (2.58) | Loss widened | (94.19) | Loss narrowed |
| EPS, basic (₹) | (2.41) | (0.10) | not comparable | (3.59) | Loss narrowed |
| Net margin (%) | -367.4 | -4.2 | -543.8 |
Standalone
- Filed with BSE
- 05 Nov 2019, 18:28 IST
- Board meeting
- 04 Nov 2019
- Period
- 01 Jul 2019 to 30 Sep 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE